C07D 215/02
Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems: having no bond
Official title: having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
C07D215/02 (Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems: having no bond) appears on 6,964 US grants and 6,267 published applications in this corpus.
Search patents in C07D- Granted patents
- 6,964
- Published applications
- 6,267
- Assignees
- 2,475
- Inventors
- 18,851
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 68 | 0 |
| 1977 | 81 | 0 |
| 1978 | 52 | 0 |
| 1979 | 43 | 0 |
| 1980 | 56 | 0 |
| 1981 | 62 | 0 |
| 1982 | 53 | 0 |
| 1983 | 63 | 0 |
| 1984 | 75 | 0 |
| 1985 | 83 | 0 |
| 1986 | 86 | 0 |
| 1987 | 86 | 0 |
| 1988 | 115 | 0 |
| 1989 | 112 | 0 |
| 1990 | 140 | 0 |
| 1991 | 126 | 0 |
| 1992 | 114 | 0 |
| 1993 | 160 | 0 |
| 1994 | 121 | 0 |
| 1995 | 144 | 0 |
| 1996 | 134 | 0 |
| 1997 | 164 | 0 |
| 1998 | 144 | 0 |
| 1999 | 118 | 0 |
| 2000 | 132 | 0 |
| 2001 | 140 | 21 |
| 2002 | 174 | 186 |
| 2003 | 170 | 240 |
| 2004 | 149 | 332 |
| 2005 | 130 | 331 |
| 2006 | 178 | 314 |
| 2007 | 159 | 279 |
| 2008 | 159 | 290 |
| 2009 | 193 | 302 |
| 2010 | 158 | 327 |
| 2011 | 199 | 261 |
| 2012 | 211 | 267 |
| 2013 | 239 | 241 |
| 2014 | 243 | 343 |
| 2015 | 263 | 269 |
| 2016 | 179 | 236 |
| 2017 | 211 | 225 |
| 2018 | 164 | 232 |
| 2019 | 201 | 219 |
| 2020 | 166 | 256 |
| 2021 | 187 | 219 |
| 2022 | 138 | 203 |
| 2023 | 117 | 215 |
| 2024 | 119 | 200 |
| 2025 | 115 | 142 |
| 2026 | 70 | 117 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- NAMPT modulators29 Sep 2026US 12,747,203 B2Cytokinetics, Inc.
- Membrane-active anti-bacterial compounds and uses thereof29 Sep 2026US 12,747,213 B2Regents of the University of Minnesota
- GluN2B-subunit selective antagonists of the N-methyl-D-aspartate receptors with enhanced potency at acidic pH29 Sep 2026US 12,747,221 B2Emory Univeristy
- Methods and compositions for treating cancer22 Sep 2026US 12,740,976 B2City of Hope
- Lipoxygenase inhibitors22 Sep 2026US 12,741,926 B2SRI International
- Crystalline forms of 3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methylsulfonyl)benzonitrile8 Oct 2026US 2026/0308126 A1
- Antidegradant bis(dihydro and tetrahydroquinoline) compounds and uses thereof8 Oct 2026US 2026/0308127 A1Flexsys IP Holdings, LLC
- Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications1 Oct 2026US 2026/0297012 A1NucMito Pharmaceuticals Co. Ltd.
- Hydroxylamine-based bcr-abl1 inhibitors for treatment of cancer1 Oct 2026US 2026/0297031 A1University of Georgia Research Foundation, Inc.
- Organic Photoredox Catalysts, Compositions, and Conversion Processes24 Sep 2026US 2026/0284647 A1Colorado State University Research Foundation
Most cited
By later US patents
- Phosphorescent compounds and devices comprising the same1,017US 6,835,469 B2Universal Display Corporation · 2004
- Material for luminescence element and luminescence element using the same890US 6,528,187 B1Fuji Photo Film Co., Ltd. · 2003
- 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use451US 4,689,338 ARiker Laboratories, Inc. · 1987
- Substituted unsymmetrical cyanine dyes with selected permeability384US 5,658,751 AMolecular Probes, Inc. · 1997
- Cyclic-substituted unsymmetrical cyanine dyes371US 5,436,134 AMolecular Probes, Inc. · 1995